Gene Liau, EVP Research & Preclinical Development at Stoke Therapeutics, Inc. (STOK), sold 38,770 shares at $25.82 ($1.0M) on 2020-06-01, disclosed to the SEC on 2020-06-03.
Open-market sale of $1.0M STOK by EVP Research & Preclinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.82 | 10,895 | $281K | 27.6% |
| 2 | $25.82 | 10,895 | $281K | 27.6% |
| 3 | $26.91 | 7,875 | $212K | 20.8% |
| 4 | $26.91 | 7,875 | $212K | 20.8% |
| 5 | $27.48 | 1,230 | $34K | 3.3% |
| Total | $26.32 avg | 38,770 |
| $1.0M |
| 100% |
| Filing → |
| STOK | SELL | 2020-10-13 | $66K | — | Filing → |
| STOK | SELL | 2020-05-26 | $225K | — | Filing → |